Literature DB >> 11881913

Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!

Ulrich Guller1, Egbert U Nitzsche, Udo Schirp, Carsten T Viehl, Joachim Torhorst, Holger Moch, Igor Langer, Walter R Marti, Daniel Oertli, Felix Harder, Markus Zuber.   

Abstract

We prospectively evaluated 31 patients with invasive breast cancer. Preoperative positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (18F-FDG) for detection of axillary lymph node metastases was compared with the histopathologic status of the sentinel lymph node (SLN). Sensitivity of PET imaging was 43%, specificity and negative predictive value were 94 and 67%, respectively. The smallest metastasis detected by PET measured 3 mm in diameter. The results of this study suggest that detection of small axillary lymph node metastases is limited by the currently achievable spatial resolution of PET imaging. Selective axillary surgery in breast cancer patients based on 18F-FDG PET is yet not possible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11881913     DOI: 10.1023/a:1013828710301

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

Review 1.  PET/CT and breast cancer.

Authors:  Barbara Zangheri; Cristina Messa; Maria Picchio; Luigi Gianolli; Claudio Landoni; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

2.  (18)F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer.

Authors:  Eun Jung Kong; Kyung Ah Chun; Ihn Ho Cho; Soo Jung Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-06-15

3.  The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.

Authors:  W H Choi; I R Yoo; J H O; S H Kim; S K Chung
Journal:  Br J Radiol       Date:  2010-11-16       Impact factor: 3.039

4.  [Axillar lymphadenectomy].

Authors:  D Oertli
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

Review 5.  Axillary lymph node echo-guided fine-needle aspiration cytology enables breast cancer patients to avoid a sentinel lymph node biopsy. Preliminary experience and a review of the literature.

Authors:  Vittorio Altomare; Gabriella Guerriero; Rita Carino; Cleonice Battista; Angelo Primavera; Annamaria Altomare; Donata Vaccaro; Alessandro Esposito; Anna Maria Ferri; Carla Rabitti
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

Review 6.  Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients.

Authors:  Giuseppe Madeddu; Angela Spanu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

Review 7.  A systematic review of FDG-PET in breast cancer.

Authors:  S Escalona; J A Blasco; M M Reza; E Andradas; N Gómez
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

Review 8.  FDG-PET for axillary lymph node staging in primary breast cancer.

Authors:  Flavio Crippa; Alberto Gerali; Alessandra Alessi; Roberto Agresti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

9.  Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.

Authors:  Jeryong Kim; Jinsun Lee; Eilsung Chang; Seongmin Kim; Kwangsun Suh; Jiyoung Sul; Insang Song; Yonghoon Kim; Chuljoo Lee
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

10.  Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.

Authors:  L Bazzola; C Foroni; D Andreis; V Zanoni; M R Cappelletti; G Allevi; S Aguggini; C Strina; M Milani; S Venturini; F Ferrozzi; R Giardini; R Bertoni; H Turley; K Gatter; P G Petronini; S B Fox; A L Harris; M Martinotti; A Berruti; A Bottini; A R Reynolds; D Generali
Journal:  Br J Cancer       Date:  2014-12-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.